Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
A GnRH superagonist used chiefly in veterinary medicine as a slow-release implant.
Also known as: Suprelorin · Ovuplant · GnRH agonist
Part of the Foundational & therapeutic peptides cluster
Overview
Deslorelin is a synthetic GnRH agonist peptide used primarily in veterinary medicine. As implants such as Suprelorin and Ovuplant, it is applied for reversible chemical castration in dogs and for ovulation timing in mares. This page is educational and is not medical advice.
Source & context
Biological / chemical source: Synthetic GnRH analog
Primary research or clinical context: Approved for veterinary use (e.g., chemical castration in dogs, ovulation timing in mares); marketed as Suprelorin and Ovuplant
Veterinary context
Deslorelin implants provide sustained GnRH receptor activation that, after an initial stimulatory phase, suppresses reproductive hormones. Veterinary applications include managing fertility and behavior in dogs, ferrets, and other species, and controlling reproduction in livestock and companion animals.
Superagonist chemistry
Like other clinical GnRH analogs, deslorelin carries a D-amino-acid substitution at position 6 and a modified C-terminus. These changes raise receptor potency and slow degradation, which is why it is described as a GnRH superagonist.
Sequence
One-letter sequence commonly cited for Deslorelin (educational; isoforms and modifications may differ):
XHWSYWLRP
X = non-canonical residue (Glutamic acid (residue 1) is pyroglutamic acid; leucine residue at position 6 is D-Trp; C-terminal proline residue at Pro-NHEt). X marks a non-canonical residue — see the structure block below. (Plotted as alanine on the wheel.)
Residues plotted ~100° apart around an α-helix — clustering of one color reveals an amphipathic face.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Deslorelin (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C64H83N17O12
- Average reference mass
- ≈ 1,282.4
Glutamic acid (residue 1) is pyroglutamic acid; leucine residue at position 6 is D-Trp; C-terminal proline residue at Pro-NHEt
- PubChem CID: 25077495
- IUPHAR ligand: 9343
- CAS RN: 57773-65-6
- UNII: TKG3I66TVE
Chemistry values: IUPHAR/BPS Guide to Pharmacology, PubChem · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 4 registered studies with “Deslorelin” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT00001521 | Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia | Phase 3 | completed | 2025-06-12 |
| NCT00080756 | Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopa | Phase 2 | unknown | 2024-08-28 |
| NCT00001190 | Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature | Phase 2 | completed | 2008-03-04 |
| NCT00001202 | Treatment of Boys With Precocious Puberty | Phase 2 | completed | 2008-03-04 |
Deslorelin — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Deslorelin (source record; form not independently established)Average reference mass: 1,282.4 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Deslorelin
What is Deslorelin?+
Deslorelin is a synthetic GnRH agonist peptide used primarily in veterinary medicine. As implants such as Suprelorin and Ovuplant, it is applied for reversible chemical castration in dogs and for ovulation timing in mares. This page is educational and is not medical advice.
What Canadian product status is recorded for Deslorelin?+
Canadian product status for Deslorelin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Deslorelin?+
Deslorelin is commonly described as approximately 9 amino acids (GnRH agonist (nonapeptide analog)).
Related peptides
References & further reading
- 1.Cowl et al. (2018). ASSESSING THE EFFICACY OF DESLORELIN ACETATE IMPLANTS (SUPRELORIN) IN ALTERNATIVE PLACEMENT SITES. J Zoo Wildl Med
- 2.Fontaine (2015). Long-term contraception in a small implant: A review of Suprelorin (deslorelin) studies in cats. J Feline Med Surg
- 3.Wolf et al. (2012). Litter size response to oestrous induction with deslorelin (Ovuplant®) in dogs. Reprod Domest Anim
- 4.Agnew et al. (2021). DESLORELIN (SUPRELORIN(®)) USE IN NORTH AMERICAN AND EUROPEAN ZOOS AND AQUARIUMS: TAXONOMIC SCOPE, DOSING, AND EFFICACY. J Zoo Wildl Med
- 5.Hemberg et al. (2006). Successful timing of ovulation using deslorelin (Ovuplant) is labour-saving in mares aimed for single ai with frozen semen. Reprod Domest Anim
- 6.Padula et al. (2003). Absorbable deslorelin implants (Ovuplant) prolong postpartum anestrus in early ovulating dairy cows. Theriogenology
- 7.McCue et al. (2002). Removal of deslorelin (Ovuplant) implant 48 h after administration results in normal interovulatory intervals in mares. Theriogenology
- 8.Palm et al. (2012). [The use of deslorelin acetate (Suprelorin®) in companion animal medicine]. Schweiz Arch Tierheilkd
- 9.PubChem — compound summary for Deslorelin (CID 16133804)
- 10.Wikipedia — Deslorelin